Felbamate protects CA1 neurons from apoptosis in a gerbil model of global ischemia

Stroke

Volumn 27, Issue 7, 1996, Pages 1236-1240

  Wasterlain, Claude G ^a,c   Adams, Lisa M ^a   Wichmann, Joseph K ^b   Sofia, R Duane ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Wallace Laboratories   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

apoptosis; cerebral ischemia; gerbils; neuroprotection

Indexed keywords

ANTICONVULSIVE AGENT; FELBAMATE; METHOXYFLURANE; PENTOBARBITAL;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; BRAIN TEMPERATURE; COMPLICATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG MEGADOSE; DRUG PENETRATION; DRUG THERAPY; GERBIL; GRANULE CELL; HIPPOCAMPUS; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PREVENTION; PRIORITY JOURNAL;

EID: 0030002689     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.27.7.1236     Document Type: Article

References (32)

1. Wallis RA, Panizzon KL. Glycine reversal of felbamate hypoxic protection. Neuroreport. 1993;4:951-954.
2. Wasterlain CG, Adams LM, Hattori H, Schwartz PH. Felbamate reduces hypoxic-ischemic brain damage in vivo. Eur J Pharmacol. 1992;212:275-278.
3. Adams LM, Schwartz PH, Palos TP, Morin AM, Wasterlain CG. Felbamate reduces neuronal necrosis and behavioral deficits induced by cardiac arrest in rats. Soc Neurosci Abs. 1992;22:610-611. Abstract.
4. Rogawski MA. Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. Trends Pharmacol Sci. 1993;14:325-331.
5. McCabe RT, Wasterlain CG, Kucharczyk N, Sofia RD, Vogel JR. Evidence for anticonvulsant and neuroprotectant action of felbamate mediated by strychnine-insensitive glycine receptors. J Pharmacol Exp Ther. 1993;264:1248-1252.
6. Coffin VL, Cohen-Williams M, Barrett A. Selective antagonism of the anticonvulsant effects of felbamate by glycine. Eur J Pharmacol. 1994;256:R9-R10.
7. De Sarro GB, Ongini E, Bertorelli R, Agugula U, De Sarro A. Excitatory amino acid neurotransmission through both NMDA and non-NMDA receptors involved in the anticonvulsant activity of felbamate in DBA/2 mice. Eur J Pharmacol. 1994;262:11-20.
8. White HA, Wolf HH, Swinyard EA, Skeen GA, Sofia RD. A neuropharmacological evaluation of felbamate as a novel anticonvulsant. Epilepsia. 1992;33:564-572.
9. Sofia RD, Gordon R, Gels M, Diamentis W. Comparative effects of felbamate and selected compounds on N-methyl-D-aspartic acid-induced convulsions and lethality in mice. Pharmacol Res. 1994;29: 139-144.
10. Wasterlain CG, Adams LM, Schwartz PH, Hattori H, Sofia RD, Wichmann JK. Posthypoxic treatment with felbamate is neuroprotective in a rat model of hypoxia-ischemia. Neurology. 1993; 43:2303-2310.
11. Nitatori T, Sato N, Waguri S, Karasawa Y, Araki H, Shibanai K, Kominami E, Uchiyama Y. Delayed neuronal death in the CA1 pyramidal cell layer of the gerbil hippocampus following transient ischemia is apoptosis. J Neurosci. 1995;15:1001-1011.
12. Loskota WL, Lomax P, Verity MA. A Stereotaxic Atlas of the Mongolian Gerbil Brain. Ann Arbor, Mich: Ann Arbor Science: 1974.
13. Jacala A, Adusumalli VE, Kucharczyk N, Sofia RD. Determination of the anticonvulsant felbamate and its three metabolites in brain and heart tissue of rats. J Chromatogr A. 1993;614:285-292.
14. Theodore WH, Reeves P, Porter RJ, Nice FJ, Derinsky O, Bromfield E, Balish M. Long-term followup of felbamate therapy in patients with complex partial seizures. Epilepsia. 1990;31:619.
15. Leppik IE, Dreyfuss FE, Pledger GW, Graves NM, Santilli N, Drury I, Tsay JY, Ashworth M, Lee SI, Sierzant TL. Felbamate for partial seizures: results of a controlled clinical trial. Neurology. 1991;41: 1785-1789.
16. Wagner ML, Leppik IE, Graves NM, Remme RP, Campbell JI. Felbamate serum concentrations: effect of valproate, carbamazepine, phenytoin and phenobarbital. Epilepsia. 1990;31:642. Abstract.
17. Garofalo EA, Olson LD, Sackellares JC, Child J, Tornow MA, Komarynski MA. Felbamate for the treatment of Lennox-Gastaut syndrome. Epilepsia. 1990;31:619. Abstract.
18. Ward DL, Wagner ML, Perhach JL, Kramer L, Graves N, Leppik I, Shumaker RC. Felbamate steady-state pharmacokinetics during coadministration of valproate. Epilepsia. 1991;329(suppl 3):8. Abstract.
19. Pennell PG, Ogaily MS, MacDonald RL. Aplastic anemia in a patient receiving felbamate for complex partial seizures. Neurology. 1995; 45:456-460.
20. Data on file. Wallace Laboratories, Cranbury, NJ.
21. Swinyard EA, Sofia RD, Kupferberg HH. Comparative anti-convulsant activity and neurotoxicity of felbamate and four prototype antiepileptic drugs in mice and rats. Epilepsia. 1986;27:27-34.
22. Sachdeo RC, Wagner LM. Felbamate in generalized tonic-clonic seizures. Epilepsia. 1992;32(suppl 3):54. Abstract.
23. Sachdeo R, Kramer LD, Rosenberg A, Sachdeo S. Felbamate monotherapy: controlled trial in patients with partial onset seizures. Ann Neurol. 1992;32:386-392.
24. Kuroiwa T, Bonnekoh P, Hossmann KA. Therapeutic window of CA1 neuronal damage defined by an ultrashort-acting barbiturate after brain ischemia in gerbils. Stroke. 1990;21:1489-1493.
25. Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 1989;244:1360-1362.
26. Troupin AS, Mendius JR, Cheng F, Risinger MW. MK-801. In: Meldrum BS, Porter RJ, eds. New Anticonvulsant Drugs: Current Problems in Epilepsy, 4. London, UK: John Libbey; 1986:191.
27. Kirino T. Delayed neuronal death in the gerbil hippocampus following ischemia. Brain Res. 1982;239:57-69.
28. Wasterlain CG, Schwartz PH, Akira T, Henry D. Does nitric oxide play a role in the amplification phase of delayed neuronal injury? In: Krieglstein J, Oberpichler-Schwenk H, eds. Pharmacology of Cerebral Ischemia. Stuttgart, Germany: Wissenschaftliche Verlagsgesellschaft GmbH; 1994:55-67.
29. Wamsley JK, Sofia RD, Faull RLM, Narang N, Ary T, McCabe RT. Interaction of felbamate with 3H DCKA-labeled strychnine-insensitive glycine receptors in human post-mortem brain. Exp Neurol. 1994;129:244-250.
30. Buchan AM, Lesiuk H, Barnes KA, Li H, Huang ZG, Smith KE, Xue D. AMPA antagonists: do they hold more promise for clinical stroke trials than NMDA antagonists? Stroke. 1993;24(suppl I): I-148-I-152.
31. Sheardown MJ, Suzdak PD, Nordholm L. AMPA, but not NMDA, receptor antagonism is neuroprotective in gerbil global ischemia, even when delayed 24 hours. Eur J Pharmacol. 1993;236: 347-353.
32. Gill R, Foster AC, Woodruff GN. MK 801 is neuroprotective in gerbils when administered during the post-ischemic period. Neuroscience. 1988;25:847-855.